Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ipilimumab N01”

3 trials

Showing 3 of 3 results

Testing effectiveness (Phase 2)Looking for participantsNCT07506109
What this trial is testing

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Who this might be right for
BRAF V600EColorectal CancerSintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07422753
What this trial is testing

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487662
What this trial is testing

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Sun Yat-sen University 105

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation